Next Investors logo grey

Creso Pharma signs exclusive agreement with Virbac


Published 08-AUG-2017 11:05 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX:CPH) has signed an exclusive commercialisation agreement with Virbac Switzerland, a global pharmaceutical animal health company, for the launch of its first original hemp-based complementary animal feed products in Switzerland.

The Swiss launch of CPH’s proprietary formulated hemp-based complementary feed products for companion animals, anibidiol® 1.25 and anibidiol® 2.5, is planned for the fourth quarter of this year.

CPH has developed and will manufacture the products, and Virbac will launch, market and promote them to veterinarians and pet-owning households.

This announcement comes on the back of the registration of hemp extract on the European Feeds Material Register earlier this year.

Importantly, a successful launch in Switzerland, which is regarded as a regulatory and marketing reference country for many countries in Europe, Latin America and Asia Pacific, will enable CPH to expand into further international markets.

The agreement starts from 1st of September, and remains in effect for at least three years.

CPH’s commercialisation debut in animal health

CPH is a leader in medicinal cannabis and cannabidiol (CBD) innovation, and develops cannabis and hemp-derived therapeutic-grade CBD nutraceuticals and medicinal cannabis products across both human and animal health sectors.

The company has had a busy year thus far: it recently signed an exclusive deal with the renowned Swiss-based Cannapharm, and has also acquired 100% of the Canadian Mernova Medicinal Inc., a deal which positions it as a Canadian producer of legal cannabis.

And with the exclusive commercialisation agreement it’s now signed with Virbac Switzerland, CPH is gaining a high-impact partner.

Virbac is a global pharmaceutical animal health company with a presence in over 100 countries, and ranks as the 7th largest pharmaceutical veterinary company worldwide. It has more than 4,800 employees and sales subsidiaries across 31 countries, and in 2016 had a turnover of €872 million (AU$1.29BN).

Virbac stats

This partnership would enable CPH to leverage Virbac’s strong worldwide presence and science-grounded experience in marketing products for companion animals.

The Swiss launch of the Anibidiol® range will also provide the veterinary market with a unique product targeting the well-being of companion animals, and will be in high demand, making this collaboration highly advantageous for both parties.

CPH’s Anibidiol® product range

Anibidiol® 1.25 and anibidiol® 2.5 are designed for companion animals, particularly cats and dogs, and come in proprietary granule formulations. The products target stress and behavioural problems, chronic pain, and age-related ailments in older animals.

Containing full plant hemp extract in proprietary formulations, these products promote well-being by supporting the immune system, the natural response, and the behavioural balance of the companion animal.

CPH’s anibidiol® products are standardised in composition and dose and in innovative proprietary delivery systems, enhancing bioavailability and absorption.

In July, the Swiss agency, Agroscope, a sub-department in the Swiss Federal Department of Economic Affairs, Education and Research (RAER) responsible for safe feed in and trade from Switzerland, provided confirmation of CPH’s adherence to Swiss feed regulations and issued Free Sales Certificates for the anibidiol® product range.

There is a clear market for non-pharmaceutical therapeutic approaches which are natural and well-tolerated by the animals – for instance, which avoid GI and dependence side-effects.

41% of pet owners have considered or tried various alternative therapies including nutritional supplements (29%) and herbal remedies (7%).

Around 57% of households across the globe are pet-owning, and 33% have dogs. This recession-resistant worldwide animal health market is estimated to be worth US$30 billion and is projected to continue rapidly growing.

Tapping into this robust market, CPH is ideally placed for its first market introduction of its hemp-based feed products in the fourth quarter of this year.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.